Monkeys infected with Ebola can be cured with a pill, according to a new study that was published Friday, March 14, that could pave the way for more practical, affordable treatments in humans.
First identified in 1976 and thought to have crossed over from bats, Ebola is a deadly viral disease spread through direct contact with bodily fluids, causing severe bleeding and organ failure. Because outbreaks primarily affect sub-Saharan Africa, pharmaceutical companies have lacked financial incentives to develop treatments, and the nature of outbreaks has made clinical trials difficult.
A vaccine was approved in 2019, and while two intravenous antibody treatments improve outcomes, they require costly cold storage and are difficult to administer in some of the world’s poorest regions.
“We’re really trying to come up with something that was more practical, easier to use, that could be used to help prevent, control, and contain outbreaks,” Thomas Geisbert, a virologist at The University of Texas Medical Branch at Galveston, who led the new study published in Science Advances, told AFP.
For their experiment, Geisbert and colleagues tested the antiviral Obeldesivir, the oral form of intravenous Remdesivir, originally developed for Covid-19.
Obeldesivir is a “polymerase inhibitor,” meaning it blocks an enzyme crucial for viral replication.
The team infected rhesus and cynomolgus macaques with a high dose of the Makona variant of the Ebola virus.
A day after exposure, ten monkeys then received an Obeldesivir pill daily for ten days, while three control monkeys received no treatment and died.
Obeldesivir protected 80 percent of the cynomolgus macaques and 100 percent of the rhesus macaques, which are biologically closer to humans.
The drug not only cleared the virus from the treated monkeys’ blood but also triggered an immune response, helping them develop antibodies while avoiding organ damage.
Geisbert explained that while the number of monkeys was relatively small, the study was statistically powerful because they were exposed to an extraordinarily high dose of the virus — roughly 30,000 times the lethal dose for humans. This reduced the need for additional control monkeys, limiting unnecessary animal deaths.
The researcher, who has worked on Ebola since the 1980s said one of the most exciting aspects of Obeldesivir is its “broad-spectrum” protection, compared to the approved antibody treatments that only work against the Zaire species of Ebola.
“That’s a huge advantage,” Geisbert said.
Pharmaceutical maker, Gilead is currently advancing Obeldesivir to Phase 2 clinical trials for Marburg virus, a close relative of Ebola.
Geisbert also emphasized the importance of funding from the US National Institutes of Health.
“All these drugs and vaccines that were developed against Ebola and a lot of these exotic viruses and pathogens — 90 percent of the money comes from the US government,” he said, adding, “I think the general public would agree we need treatments for Ebola.”
Source: Linda Ikeji Blog
